Albuquerque, NM, July 30, 2026 – Indica Labs today announces the launch of the HALO® ADC Target Scoring module, a powerful new functionality that supports the development of next-generation precision oncology therapies through quantitative target scoring and spatial analysis.
We’re excited to announce the launch of our new ADC Target Scoring module, designed to support continuous quantitative measurement of target protein expression across different cellular compartments.
HALO® ADC Target Scoring Module Features and Functionalities Read More »
Albuquerque, NM, July 28, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced new intelligent tissue classification capabilities for HALO Breast IHC AI, its AI-powered breast biomarker quantification suite, seamlessly deployed in HALO AP®. This enhanced new version introduces fully automated identification and exclusion of positive control tissue, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and areas of benign tissue prior to biomarker analysis. This zero-click preprocessing and tissue classification workflow represents a critical step in ensuring accurate and reproducible AI outputs.
In this blog post, we’ll discuss some of the exciting new features and functionalities in the latest release of HALO AP®, the CE-IVDR marked, AI-powered enterprise digital pathology platform from Indica Labs.
Zero-Click Breast IHC Scoring Is Here: What’s New in HALO Breast IHC AI Read More »
In this blog post, you can learn about the new features coming in version 4.3 of HALO®, HALO AI, and HALO Link, when to expect your chance to upgrade, and where to find user guides, release notes, and tutorial videos.
HALO®, HALO AI, and HALO Link 4.3 Features and Functionalities Read More »
Streamline analysis for antibody-drug conjugate (ADC)-focused assays and perform quantitative continuous scoring and spatial analysis.
New! ADC Target Scoring Module Read More »
In this blog post, we’ll discuss some of the exciting new features and functionalities in the latest release of HALO AP®, the CE-IVDR marked, AI-powered enterprise digital pathology platform from Indica Labs.
HALO AP 2.5: Scaling Digital Pathology with Intelligent Workflow Orchestration Read More »
Albuquerque, NM, July 14, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced a new software release designed to streamline and scale digital pathology workflows through enhanced automation, collaboration, and system transparency.
Albuquerque, NM, June 30, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the launch of Prostate Macrodissect AI, a clinically validated algorithm designed to automate and quantify tumor content in FFPE prostate tissue specimens. Prostate Macrodissect AI is designed to operate in concert with Indica Labs’ broader HALO Clinical AI suite, enabling laboratories to build end-to-end AI-powered prostate cancer workflows from automated tumor detection and Gleason grading assistance through to optimized macrodissection and genomic test preparation within a single, validated digital pathology platform.
HALO AP 2.5 introduces Lab Logic. A configuration layer that enables labs to tailor HALO AP® to their preferred workflow, enabling any lab, regardless of case volume, to operate like an automated triage engine, continuously analyzing incoming slides; triggering AI-driven actions; and delivering the right cases to the right experts at the right time.
Lab Logic Brings Intelligent Case Orchestration to HALO AP® and HALO AP Dx Read More »
